BioMarin Signs License Deal for Fabry Disease Therapy Candidate

MT newswire2026/10/29 14:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

10:45 AM EDT, 10/29/2026 (MT Newswires) -- BioMarin Pharmaceutical (BMRN) said Thursday it has signed a licensing deal with GC Biopharma and Hanmi Pharm to develop and commercialize HM15421/GC1134A for Fabry disease. The agreement is for exclusive worldwide rights, excluding South Korea, to the clinical-stage enzyme replacement therapy for Fabry disease, the company said. BioMarin said it will pay $70 million upfront, with an additional $405 million payments upon certain development and commercial milestones, and tiered royalties. Price: 56.70, Change: +0.70, Percent Change: +1.25

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03